Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF

Rajesh K. Sharma,¹ Anna T. Rogojina,² K.V. Chalam¹

¹Department of Ophthalmology, University of Florida, Jacksonville FL; ²St. Jude Children’s Research Hospital, Memphis TN

Purpose: Vascular endothelial growth factor (VEGF) plays a key role in neovascularization by stimulating the proliferation and migration of vascular endothelial cells. The anti-VEGF therapy bevacizumab acts by binding to VEGF and preventing its effects. However, this linear interaction represents only a partial view of the pathobiology of neovascular diseases and the anti-VEGF treatment. To obtain an integrated view of the processes involved in VEGF-related ocular pathologies, we applied a systems approach and investigated whether intravitreal bevacizumab injections have a global effect in normalizing the ocular physiology perturbed by the disease.

Methods: We analyzed 90 analytes representing various pathophysiological processes in aqueous humor. The samples were obtained from eight patients receiving intravitreal bevacizumab injections for various ocular VEGF-related conditions. The samples were obtained before and after the injection and were analyzed using microbead technology developed by Luminex xMAP.

Results: Forty-three analytes were detected above the sensitivity of the assay both in pre- and post-injection samples. Of these, normal values of 41 analytes were known and these analytes were further analyzed. The detected analytes included relevant markers such as VEGF, C reactive protein, glutathione, and cytokines. We identified 24 markers that were perturbed more than 1.5 fold in diseased samples (pre-injection) compared to normal levels. The levels of perturbed analytes were compared in post-treatment samples. The results demonstrated an unequivocal trend toward normalization in post-treatment samples.

Conclusions: Our results show intraocular bevacizumab injections change the perturbed physiologic environment of the eye toward normalization. Its effects reached beyond neutralizing VEGF. The results also demonstrate that large-scale analysis of the aqueous, using a systems approach, could provide useful insight regarding ocular diseases, their pathophysiology, and treatment responses.

Neovascularization, a common pathology in several diseases, results from complex interactions between pro and antiangiogenic cytokines involving multiple pathways. Of the various cytokine families that play roles in the development, maintenance, and remodeling of microcirculation, the vascular endothelial growth factor (VEGF) family is the most complex and most studied. Vascular endothelial growth factor stimulates the cell proliferation, migration, and survival of vascular endothelial cells [1,2]. Anti-VEGF therapy has become a widely accepted treatment for several diseases where neovascularization and permeability plays a pivotal role, including cancer and retinal disorders. Anti-VEGF therapy, including bevacizumab, acts by binding to VEGF and preventing its cellular effects. However, this linear interaction represents only a partial view of the pathobiology of the disease and treatment processes. Consequently, the classical concept of linear interactions is being replaced by the concept of networks of interactions, emphasizing the importance of interactions between different components of a biologic system [3]. With a large number of interacting components in the process of neovascularization, focus on a single or a small number of molecules imposes the risk making incomplete and flawed interpretations. For such a complex process, a systems biology approach can provide useful insights.

Beyond genetic and environmental determinants, diseases are characterized by a perturbed physiology. Therefore, methods providing deeper insights into physiologic states are essential in acquiring an integrated view of human disease [4]. Spectacular progresses in quantitative techniques, large-scale measurement methods, and integration between experimental and computational approaches has made it possible to understand organisms, their physiology, and pathobiology at the system level. Applications of such system-wide approaches to human biology, ushered in by the human genome project, are likely to open new opportunities in medicine.

We have previously demonstrated that using a microbead assay, a quantitative analysis of a large number of analytes in aqueous humor can provide useful system-wide information about the pathophysiological intraocular environment [5]. We can simultaneously monitor concurrent activities of multiple molecules using this approach, enabling a broader and
unbiased view of biologic events. In the current study, we applied the same methodologies to investigate how VEGF-related diseases of the eye change the intraocular environment and whether anti-VEGF therapy has a system-wide effect on normalizing the perturbed ocular environment.

**METHODS**

Samples: Aqueous humor was obtained from eight patients undergoing bevacizumab injections for various VEGF-related ocular pathologies. Of the eight patients, three were male and five were female. Two patients were treated for central retinal vein occlusion (CRVO), one for branch retinal vein occlusion (BRVO), two for clinically significant macular edema (CSME), and three for age-related macular degeneration (AMD). The samples were drawn sequentially on two different occasions from the same patient. The first sample (pre-treatment sample) was drawn just before the first intravitreal bevacizumab injection (0.125 mg), representing the pathological sample. The second sample (post-treatment sample) was drawn before the second intravitreal injection of bevacizumab, representing the effect of treatment on the aqueous profile after the eye was injected with 0.25 mg of bevacizumab. Aqueous humor (80–100 µl) was withdrawn through a limbal paracentesis site using a 27-gauge needle in a tuberculin syringe. Care was taken to avoid touching intraocular tissues and to prevent contamination of aqueous samples with blood. The samples were immediately frozen and stored at −80 °C. Patients with other ocular or systemic disease, such as inflammatory diseases, were excluded from the study.

Informed consent was obtained from the patients, and the research was in compliance with the tenets of the University of Florida and the Declaration of Helsinki for experiments involving human tissue.

Multiplex analysis: Multiplex analysis was performed at Rules-Based Medicine (Austin, TX), which uses multi-analyte profiles (MAPs) based on powerful Luminex xMAP® (Luminex Corporation, Austin TX) technology to discover biomarker patterns within very small sample volumes. The aqueous samples were thawed at room temperature, vortexed, and spun at 13,000× g for 5 min to remove any precipitates. The maximum available volume (80–100 µl) was removed for MAP antigen analysis into a master microtiter plate. Using automated pipetting, an aliquot of each sample was introduced into one of the capture microsphere multiplexes of the human antigen MAP. These mixtures of sample and capture microspheres were thoroughly mixed and incubated at room temperature for 1 h. Multiplexed cocktails of biotinylated reporter antibodies for each multiplex were then added robotically and were thoroughly mixed. The mixture was then incubated for an additional 1 h at room temperature. Multiplexes were developed using an excess of streptavidin-phycocerythrin solution, which was thoroughly mixed into each multiplex and incubated for 1 h at room temperature. The volume of each multiplexed reaction was reduced by vacuum filtration and the volume increased by dilution into matrix buffer for analysis. Analysis was performed in a Luminex 100 instrument and the resulting data stream was interpreted using proprietary data analysis software (developed at Rules-Based Medicine and licensed to Qiagen Instruments, Valencia, CA). For each multiplex, both calibrators and controls were included on each microtiter plate. Eight-point calibrators were run in the first and last column of each plate and three-level controls were included in duplicate. Testing results were determined first for the high, medium, and low controls for each multiplex to ensure proper assay performance. Unknown values for each of the analytes localized in a specific multiplex were determined using four and five parameters and weighted and non-weighted curve fitting algorithms included in the data analysis package.

Analysis: The value for each analyte was obtained as a concentration (e.g., mg/ml). The values of eight samples (or less if an analyte could not be analyzed in all samples because of insufficient quantity of the sample) were averaged and compared to the sensitivity of the system. An analyte was considered “detectable” if the levels exceeded the minimal detectable levels. The standard deviation for the detected analytes was calculated using an Excel® (Microsoft, Redmond, VA) spreadsheet. The pre-treatment levels were compared with previously published data on normal aqueous samples that were obtained from patients undergoing cataract surgery without any other ocular pathology. The data on normal samples was previously published [5]. Since the microbead assay is highly reproducible [6], it is therefore possible to compare values from different assays. Thus, the previously published results were used as a control for pre- and post-treatment samples. The pre-treatment samples were also compared with the post-treatment samples to elucidate the effect of intravitreal bevacizumab injections. Further, cluster analysis was performed on the analytes detected in all three conditions (normal, pre-treatment, and post-treatment). For cluster analysis, the gene ID for the analytes was identified and log values of the data were used to import them to Cluster and Treeview software. Red indicates upregulated analytes and green indicates low expression. The purpose of cluster analysis was to provide an easily appreciable global view of changes in analyte values in normal, pre-treatment and post-treatment samples.

Statistical analysis: Tukey’s post-hoc test was used to determine the significant differences in two groups of analytes (pre-treated versus normal and post-treated versus normal). Unsupervised hierarchical average-link clustering using Cluster and Treeview (Eisen Laboratory, Stanford University, Palo Alto, CA) was done to find patterns in analyte expression levels.

**RESULTS**

A total of 90 analytes represented on MAP analytes were analyzed. Of the 90 analytes, 43 were detected in pre- and
post-samples above the detectable limits. Of the 43 analytes, we obtained control values (values from aqueous obtained from non-pathological eyes) for 41. Two analytes (interleukin-7 [IL-7] and inter-cellular adhesion molecule-1 [ICAM-1]) were detected in pre- and post-treatment samples, but not in control samples. A list of analytes detected in all the samples is provided in Table 1. These 41 analytes were further analyzed. Further analysis revealed that of 41 analytes common to the control and pre-treatment samples, 10 were down-regulated in pre-treatment samples and 31 were upregulated (Figure 1). Of the 43 analytes common to pre- and post-treatment samples, seven analytes were upregulated compared to the pre-treatment samples and the other 36 were down-regulated, suggesting a trend toward normalization (Figure 2). To further confirm this observation, the 41 analytes that were common to pre- and post-treatment samples and were also reported in normal samples were individually compared to see if the changes observed in the pre-treatment samples (aqueous from diseased eyes) as compared to control samples (normal values) were reversed after bevacizumab injection in post-treatment samples. Toward this goal, we identified 24 analytes that demonstrated a 1.5 fold or more difference (upregulation or down-regulation) in pre-treatment samples as compared to the normal samples; then we compared this change to the post-treatment samples. This cut-off limit was chosen to eliminate analytes that might have shown some differences merely by chance when compared to controls. Values between a 1.5 and threefold change are generally used in gene expression studies [7-9]. Although these studies relate to microarray analysis, it is reasonable to employ similar cut-off limits to other studies such as this. The upregulated analytes included IL-6, IL-8, erythropoietin, basic fibroblast growth factor (bFGF), CD40, C-reactive protein, fibronogen, VEGF, and tissue inhibitor of metalloproteinase (TIMP-1). The down-regulated analytes included glutathione s-transferase, complement 3 (MMP3), erythropoietin, bFGF, TIMP-1, CD40, C reactive protein, endothelin, and glutathione S-transferase are implicated in ocular pathologies and therefore their measurement could provide useful information [12-15]. The changes observed in pathological samples were consistent with the neovascular and permeability-related pathophysiology. Analytes relevant to neovascular pathology that showed increased levels included IL-6, C reactive protein, fibronogen, IL-8, VEGF, MMP-3, erythropoietin, CD40, bFGF, and TIMP-1 [16,17]. Similarly relevant for neovascular pathophysiology were glutathione S and IGF-1, which were down-regulated in aqueous samples [18,19]. It may be noted that the standard deviations for many analytes in this study were relatively large. This reflects the wide range of analyte values among different patients. We did not make any effort to control the recruitment of patients based on the level of analyte. Therefore, the level of analytes present in the aqueous varies widely between the individuals (range was large), reflecting individual variation, disease process, and the stages of disease.

Most significantly, this study demonstrated that the effect of anti-VEGF therapy on the in oculo pathophysiological environment extended beyond neutralization of VEGF [20]. We identified 24 analytes that were distinctly changed (1.5 fold or more) in the aqueous from the pathological samples as compared to normal values. Analysis of these analytes in the same patients after the bevacizumab injection demonstrated that all analytes upregulated in pre-treatment tended to normalize after the treatment. Many of these analytes are not directly related to the function of VEGF. These results provide strong and unequivocal evidence that the bevacizumab

**DISCUSSION**

Multi-analyte profiles are a fully validated technique [10] based on Luminex technology. This assay performs up to 100 multiplexed, microsphere-based assays in a single reaction vessel by combining optical classification schemes, biochemical assays, flow cytometry, and advanced digital signal processing hardware and software. Research Based Medicine’s MAPs represent the number of markers relevant to neovascular pathology such as hormones, cytokines/chemokines, acute phase reactants, clotting proteins, growth factors, tissue modeling factors, and other typical plasma proteins [11]. Using MAPs to measure a broad spectrum of biomarkers, a comprehensive analysis of intraocular physiologic status can be obtained [5]. We hypothesized that such an analysis could be useful in understanding the pathobiology of a disease, assessing its progression, or assessing the response to a treatment. We provided the proof of principle by comparing two diabetic samples and demonstrating relevant differences in aqueous profiles [5]. In the current study, we used this technique to study how an aqueous profile consisting of 90 analytes represented on the MAP differed in pathological samples compared to previously published values from non-neovascular (normal) samples. We further analyzed post-treatment samples from the same patients to see whether the aqueous humor profile normalized after intravitreal injection. Using the same multiplex in our previous study, we provided baseline values of 52 analytes. Since microbead assays are highly reproducible, it permits inter-experiment comparison [6]. Therefore, we were able to compare pre- and post-treatment values with previously published normal values. Many of the detected analytes such as IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), fibrinogen, VEGF, matrix metalloproteinase 3 (MMP3), erythropoietin, bFGF, TIMP-1, CD40, C reactive protein, endothelin, and glutathione S-transferase are implicated in ocular pathologies and therefore their measurement could provide useful information [12-15]. The changes observed in pathological samples were consistent with the neovascular and permeability-related pathophysiology. Analytes relevant to neovascular pathology that showed increased levels included IL-6, C reactive protein, fibronogen, IL-8, VEGF, MMP-3, erythropoietin, CD40, bFGF, and TIMP-1 [16,17]. Equally relevant for neovascular pathophysiology were glutathione S and IGF-1, which were down-regulated in aqueous samples [18,19]. It may be noted that the standard deviations for many analytes in this study were relatively large. This reflects the wide range of analyte values among different patients. We did not make any effort to control the recruitment of patients based on the level of analyte. Therefore, the level of analytes present in the aqueous varies widely between the individuals (range was large), reflecting individual variation, disease process, and the stages of disease.

Most significantly, this study demonstrated that the effect of anti-VEGF therapy on the in oculo pathophysiological environment extended beyond neutralization of VEGF [20]. We identified 24 analytes that were distinctly changed (1.5 fold or more) in the aqueous from the pathological samples as compared to normal values. Analysis of these analytes in the same patients after the bevacizumab injection demonstrated that all analytes upregulated in pre-treatment tended to normalize after the treatment. Many of these analytes are not directly related to the function of VEGF. These results provide strong and unequivocal evidence that the bevacizumab
treatment affects the pathophysiological state of the eye beyond what could be expected by neutralization of VEGF alone. These results were confirmed by a global view of the changes provided by the cluster analysis. The purpose of cluster analysis in this study was not to group analytes, but rather to use the color coding that expresses the analyte levels to show how all the analytes in Table 1 changed in three different conditions. It is apparent from looking at Figure 4 that bevacizumab treatment had a wide-ranging impact on the aqueous profile toward normalization. It is possible that some of the changes noted may be the result of the regression of the disease process (indirect effect of the treatment) or the reestablishment of the blood-retinal barrier rather than the direct effect of the bevacizumab injection.

Clinical observations suggest that the bevacizumab treatment changes the clinical course of neovascularization in a manner that cannot be entirely explained by the VEGF neutralizing effect of bevacizumab. For instance, intracameral injection of bevacizumab for iris neovascularization lasts longer than bevacizumab availability in the aqueous [20].

| Analyte                           | Units | Pre-treatment | Pre-treatment | Post-treatment | Post-treatment |
|-----------------------------------|-------|---------------|---------------|----------------|---------------|
| Alpha-1 Antitrypsin              | mg/ml | 0.0022        | 0.0012        | 0.0025         | 0.0011        |
| Alpha-Fetoprotein                | ng/ml | 0.2626        | 0.0569        | 0.2790         | 0.0636        |
| Apolipoprotein A1                | mg/ml | 0.0007        | 0.0008        | 0.0004         | 0.0004        |
| Apolipoprotein CIII              | ug/ml | 0.0424        | 0.0188        | 0.0259         | 0.0032        |
| Apolipoprotein H                 | ug/ml | 0.8176        | 0.7303        | 0.6400         | 0.5762        |
| Beta-2 Microglobulin             | ug/ml | 0.4088        | 0.3180        | 0.3026         | 0.1879        |
| C Reactive Protein               | ug/ml | 0.1114        | 0.1521        | 0.0477         | 0.0514        |
| Cancer Antigen 125               | U/ml  | 1.7363        | 0.4314        | 1.7225         | 0.3476        |
| CD40                             | ng/ml | 0.0676        | 0.0598        | 0.0510         | 0.0334        |
| Complement 3                     | mg/ml | 0.0013        | 0.0007        | 0.0014         | 0.0010        |
| Endothelin-1                     | pg/ml | 5.4863        | 1.7494        | 5.2375         | 0.6159        |
| Eotaxin                          | pg/ml | 17.7750       | 4.6849        | 13.5813        | 5.1661        |
| Erythropoietin                   | pg/ml | 120.5875      | 125.032       | 111.6125       | 130.0555      |
| FGF basic                        | pg/ml | 52.2375       | 18.8596       | 30.8900        | 20.8668       |
| Fibronogen                       | mg/ml | 0.0011        | 0.0018        | 0.0005         | 0.0005        |
| G-CSF                            | pg/ml | 17.2825       | 31.2826       | 3.6748         | 2.8391        |
| Glutathione S-Transferase        | ng/ml | 0.1406        | 0.0164        | 0.1544         | 0.0154        |
| Haptoglobin                      | mg/ml | 0.0005        | 0.0005        | 0.0004         | 0.0005        |
| IgA                              | mg/ml | 0.0014        | 0.0011        | 0.0015         | 0.0016        |
| IGF-1                            | ng/ml | 1.4248        | 0.7489        | 1.4285         | 0.8083        |
| IgM                              | mg/ml | 0.0013        | 0.0012        | 0.0009         | 0.0008        |
| IL-6                             | pg/ml | 120.2543      | 293.001       | 15.2016        | 19.9466       |
| IL-8                             | pg/ml | 22.9475       | 30.8635       | 14.9900        | 9.5664        |
| Leptin                           | ng/ml | 0.3806        | 0.5658        | 0.2131         | 0.3830        |
| MCP-1                            | pg/ml | 638.0000      | 618.982       | 438.3750       | 263.5244      |
| MIP-1alpha                       | pg/ml | 10.3625       | 3.0867        | 9.4175         | 2.4535        |
| MIP-1beta                        | pg/ml | 24.8738       | 20.2587       | 21.7988        | 14.5772       |
| MMP-3                            | ng/ml | 0.6362        | 1.2937        | 0.7259         | 0.4960        |
| PAPP-A                           | U/ml  | 0.0526        | 0.0558        | 0.0432         | 0.0306        |
| Prostate Specific Antigen, Free  | ng/ml | 0.0169        | 0.0066        | 0.0092         |                |
| Prostatic Acid Phosphatase       | ng/ml | 0.0260        | 0.0273        | 0.0095         | 0.0054        |
| Serum Amyloid P                  | ug/ml | 0.0287        | 0.0303        | 0.0134         | 0.0081        |
| SGOT                             | ug/ml | 1.8149        | 0.6531        | 1.3488         | 0.3111        |
| SHBG                             | nmol/l| 0.5133        | 0.3151        | 0.2250         | 0.0866        |
| Stem Cell Factor                 | pg/ml | 19.9938       | 6.1891        | 19.4375        | 2.5757        |
| Thyroid Stimulating Hormone      | U/ml  | 0.0293        | 0.0252        | 0.0188         | 0.0107        |
| Thyroxine Binding Globulin       | ug/ml | 0.6370        | 0.6607        | 0.3876         | 0.3822        |
| TIMP-1                           | ng/ml | 30.9825       | 29.6818       | 22.3825        | 14.0693       |
| Tissue Factor                    | ng/ml | 0.3724        | 0.0820        | 0.3631         | 0.0698        |
| VEGF                             | pg/ml | 679.6250      | 299.134       | 484.1250       | 346.3955      |
| ICAM-1                           | ng/ml | 0.7900        | 0.7117        | 0.6971         | 0.4189        |
| IL-7                             | pg/ml | 11.4175       | 1.5109        | 12.3125        | 1.1753        |

This shows the mean values and standard deviation (SD) of 41 analytes that were detectable and for which control values were available. SD=Standard Deviation.
Figure 1. Differences in normal and pathological samples. The figure shows the fold change in the analyte profile in the aqueous humor of patients with VEGF-related pathologies (pre-treatment samples) as compared to known normal values. The 41 analytes that were detected in the aqueous humor of the eyes with VEGF-related pathology were compared with the normal values previously published. The changes are presented as fold change. Ten analytes were down-regulated and 31 were upregulated.
Figure 2. Changes after treatment compared to pretreatment values. The figure shows fold change in the analyte profile in the aqueous humor of patients with VEGF-related pathologies (pre-treatment samples) as compared to the aqueous profile of treated patients (post-treatment). Forty-three analytes were common in pre- and post-treatment samples; out of these, seven analytes were upregulated and the other 36 were down-regulated, suggesting a trend toward normalization.
Figure 3. Trend toward normalization of pathological analyte profile after bevacizumab treatment. This figure shows a comparison of 24 analytes that showed a 1.5 fold or more change in the aqueous of eyes with VEGF-related pathology as compared to normal values. The effect of treatment on the analyte profile was followed by analyzing the samples from the same patients after treatment. The figure shows that all analytes upregulated in pre-treatment samples showed a trend toward normalization. Two groups of analytes (pre-treated versus normal and post-treated versus normal) were compared for each analyte using the Tukey’s post-hoc comparison test. Stars show significant differences (p<0.05) between pre-treated versus normal.
Figure 4. Cluster analysis to provide a global view of changes in all 41 analytes in pre- and post-treatment samples as compared to normal. Log values were used for importing data to Cluster and Treeview software. Red indicates upregulated analytes; green indicates low expressed analytes. The left column shows control values, the middle column shows post-treatment values, and the right column shows pre-treatment values.
considering aqueous is produced at a rate of 2–3 µl/min and
the volume of anterior chamber is approximately 250 µl.
Similarly, the effect of intravitreal injection of bevacizumab
lasts for months, longer than the bioavailability of
bevacizumab [21,22]. In addition, bevacizumab treatment not
only arrests the progression of neovascularization, but in
many cases reverses it, which again cannot be explained by
the effect of VEGF on endothelial cell proliferation and
migration alone [20]. Our results provide clues that the trend
toward the global normalization of the ocular physiologic
environment by bevacizumab injection could alter the
pathophysiology of the disease process and thus potentially
provide an explanation for these observations.

One of the limitations of the study was that the MAPs we
used were not specifically designed for ocular pathologies.
However, based on this technology, ocular pathology-specific
MAPs could be designed. These results suggest that
expression profiling of the aqueous by specifically designed
MAPs could provide valuable insight into the disease
processes and treatment responses using a systems approach.
Such an approach could facilitate deduction of the complex
networks that underlie biologic processes and characterization
of their state when perturbed by disease [23]. This approach
would aid understanding of the various aspects of diseases,
including their classification, pathobiology, treatment
responses, and prognoses [24] as well as open the door for
personalized, tailored strategies for ocular diseases at all
levels of management.

ACKNOWLEDGMENTS
This study was partly funded by the Dean’s Grant Support,
University of Florida, Jacksonville, FL to R.K.S., other funds
were provided from departmental resources.

REFERENCES
1. Bhattacharya R, Kwon J, Li X, Wang E, Patra S, Bida JP, Bajzer
Z, Claesson-Welsh L, Mukhopadhyay D. Distinct role of
PLCβ-3 in VEGF-mediated directional migration and
vascular sprouting. J Cell Sci 2009; 122:1025-34. [PMID:
19295129]
2. Hervé MA, Buteau-Lozano H, Mourah S, Calvo F, Perrot-
Applanat M. VEGF189 stimulates endothelial cells
proliferation and migration in vitro and up-regulates the
expression of Flk-1/KDR mRNA. Exp Cell Res 2005;
309:24-31. [PMID: 15996656]
3. Loscalzo J, Kohane I, Barabasi AL. Human disease
classification in the postgenomic era: a complex systems
approach to human pathobiology. Mol Syst Biol 2007;
3:124. [PMID: 17625512]
4. Martin M, Reidhaar-Olson JF, Rondinone CM. Genetic
association meets RNA interference: large-scale genomic
screens for causation and mechanism of complex diseases.
Pharmacogenomics 2007; 8:455-64. [PMID: 17465709]
5. Sharma RK, Rogojina AT, Chalam KV. Multiplex
immunoassay analysis of biomarkers in clinically accessible
quantities of human aqueous humor. Mol Vis 2009;
15:60-9. [PMID: 19145248]
6. Curnow SJ, Falciani F, Durrani OM, Cheung CM, Ross EJ,
Wloka K, Rauz S, Wallace GR, Salmon M, Murray PI.
Multiplex bead immunoassay analysis of aqueous humor
reveals distinct cytokine profiles in uveitis. Invest
Ophthalmol Vis Sci 2005; 46:4251-9. [PMID: 16249505]
7. Yuan L, Hillman JD, Progulske-Fox A. Microarray analysis of
quorum-sensing-regulated genes in Porphyromonas
gingivalis. Infect Immun 2005; 73:4146-54. [PMID:
15972504]
8. Schachter PP, Ayesh S, Matouk I, Schneider T, Czerniak A,
Hochberg A. Differential expression of kinase genes in
primary hyperparathyroidism: adenoma versus normal and
hyperparathyroid tissue. Arch Pathol Lab Med 2007;
131:126-30. [PMID: 17227113]
9. Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H,
Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A,
Martiat P. Van den BA. Insights into gene expression changes
impacting B-cell transformation: cross-species microarray
analysis of bovine leukemia virus tax-responsive genes in
ovine B cells. J Virol 2006; 80:1922-38. [PMID:
16439548]
10. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL,
Vonderfecht SL, Na S. Adoptive transfer of in vitro-
stimulated CD4+CD25+ regulatory T cells increases bacterial
clearance and improves survival in polymicrobial sepsis.
J Immunol 2005; 174:7141-6. [PMID: 15905557]
11. Gurbel PA, Kreutz RP, Blieden KP, Dichiara J, Tantry US.
Biomarker analysis by fluorokine multianalyte profiling
distinguishes patients requiring intervention from patients
with long-term quiescent coronary artery disease: a potential
approach to identify atherosclerotic disease progression.
Am Heart J 2008; 155:56-61. [PMID: 18082490]
12. Symeonidis C, Diza E, Papakonstantinou E, Souliou E,
Dimitrakos SA, Karakiuilakis G. Correlation of the extent
and duration of rheumatogenous retinal detachment with the
expression of matrix metalloproteinasises in the vitreous.
Retina 2007; 27:1279-85. [PMID: 18046238]
13. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ,
Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta
TS, Hageman GS, Immonen I, Meri S. Y402H polymorphism
of complement factor H affects binding affinity to C-reactive
protein. J Immunol 2007; 178:3831-6. [PMID: 17339482]
14. Wang X, Baldridge WH, Chauhan BC. Acute endothelin-1
application induces reversible fast axonal transport blockade
in adult rat optic nerve. Invest Ophthalmol Vis Sci 2008;
49:961-7. [PMID: 18326719]
15. Wittmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO.
Vascular endothelial growth factors and angiogenesis in eye
disease. Prog Retin Eye Res 2003; 22:1-29. [PMID:
12597922]
16. Simó R, Carrasco E, García-Ramírez M, Hernandez C.
Angiogenic and antiangiogenic factors in proliferative
diabetic retinopathy. Curr Diabetes Rev 2006; 2:71-98.
[PMID: 18220619]
17. Bulcão C, Ferreira SR, Giuffrida FM, Ribeiro-Filho FF. The
new adipose tissue and adipocytokines. Curr Diabetes Rev
2006; 2:19-28. [PMID: 18220614]
18. Kim SK, Novak RF. The role of intracellular signaling in
insulin-mediated regulation of drug metabolizing enzyme
gene and protein expression. Pharmacol Ther 2007;
113:88-120. [PMID: 17097148]
19. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14:129-51. [PMID: 9679667]
20. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous VEGF levels in neovascular glaucoma. Br J Ophthalmol 2009; 93:273-4. [PMID: 9679667]
21. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146:508-12. [PMID: 18635152]
22. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51:1606-8. [PMID: 19875666]
23. Ergün A, Lawrence CA, Kohanski MA, Brennan TA, Collins JJ. A network biology approach to prostate cancer. Mol Syst Biol 2007; 3:82. [PMID: 17299418]
24. Knickerbocker T, Chen JR, Thadhani R, MacBeath G. An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol Syst Biol 2007; 3:123. [PMID: 17593911]